News

Humira has been approved for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other

The transaction is expected to close in the first quarter of 2008, subject to required government approvals. Financial terms have not been disclosed. Sr Jose Martin, spokesperson for

Patients in the study were followed for six months. The company said that technical success was achieved in 98% of the patients. The side effects of fibroids such

Sugammadex is specifically designed to rapidly reverse the effects of certain muscle relaxants, rocuronium bromide (marketed in the US as Zemuron and in Japan as Eslax), as well

Teva’s Pravastatin sodium tablets, 80mg are the AB-rated generic equivalent of Bristol-Myers Squibb’s Pravachol 80mg tablets, and are indicated for treatment of certain hyperlipidemias and the primary prevention

Under a global collaboration, Bayer HealthCare Pharmaceuticals will support the launch of Recothrom in the US for three years. The FDA approval triggers a $40 million milestone payment

The company plans to expand the clinical trial of systemic ADH-1 in combination with isolated limb infusion melphalan for the treatment of melanoma by up to 25 additional

The first Phase I clinical study will be performed in Denmark, with the first subject expected to be recruited in the study soon. The trial is a double-blind

The FDA has agreed that Novagali may proceed with Phase I clinical trials in the US in patients with diabetic macular edema (DME) aiming to evaluate the safety